Bolt Biotherapeutics’ (BOLT) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q3 2025 earnings at ($0.33) EPS.

Separately, Stifel Nicolaus lowered their target price on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a report on Tuesday. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Trading Down 0.1 %

Shares of BOLT opened at $0.44 on Tuesday. The firm has a market capitalization of $16.82 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. Bolt Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.56. The company has a 50-day moving average of $0.47 and a 200 day moving average of $0.55.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. On average, research analysts expect that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at $42,000. Millennium Management LLC bought a new position in shares of Bolt Biotherapeutics in the 4th quarter worth $25,000. Squarepoint Ops LLC purchased a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth $26,000. Finally, Velan Capital Investment Management LP bought a new stake in Bolt Biotherapeutics during the fourth quarter valued at about $27,000. 86.70% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.